A Lung Cancer Patient Harboring a Rare Oncogenic EGFR Exon 20 V786M Mutation Responded to a Third-Generation Tyrosine Kinase Inhibitor: Case Report and Review of the Literature

Qi Zhu, Mingyun Jiang, Wenfei Li, Shuangli Sun, Jisheng Li, Justin Stebbing, Xiaodong Liang, Ling PengFrontiers in Oncology 2022 · DOI

This case report, published in Frontiers in Oncology, provides a detailed clinical and structural analysis of a rare EGFR mutation in non-small cell lung cancer (NSCLC). By combining real-world clinical outcomes with computational protein modeling, the authors demonstrate that the rare V786M mutation is an oncogenic driver that can be successfully targeted with third-generation tyrosine kinase inhibitors (TKIs).

TL;DR

Researchers identified a rare EGFR Exon 20 point mutation (V786M) in a lung cancer patient that failed to respond to immunotherapy and first-generation TKIs but showed a remarkable partial response to the third-generation TKI almonertinib. Structural modeling reveals that this mutation facilitates receptor dimerization to drive cancer growth while leaving the drug-binding pocket accessible for targeted therapy.

What Problem Does This Paper Address?

While "classical" EGFR mutations (like Exon 19 deletions) have well-established treatment protocols using TKIs, "uncommon" mutations—which account for 10%–20% of EGFR-mutant NSCLC—remain a "gray zone" in oncology.

Specifically, mutations in Exon 20 are often associated with de novo resistance to standard TKIs. Most Exon 20 issues are "insertions," but rare point mutations like V786M also exist. Because V786M appears in only about 0.5% of lung cancer patients, clinical data on how to treat it is extremely scarce. This paper addresses the lack of evidence-based treatment strategies for these "orphan" mutations.

Methods

The study employs a dual approach:

  1. Clinical Case Study: The authors track a 69-year-old female patient through four lines of therapy, including chemotherapy, immune checkpoint inhibitors (ICIs), and two different generations of EGFR TKIs.
  2. Computational Structural Biology: To understand why the drug worked, the team used I-TASSER to predict the 3D structure of the mutant EGFR protein. They performed docking simulations to compare how ATP and TKIs bind to the V786M mutant versus the wild-type protein.
  3. Literature Review: The authors aggregated data from eight previously reported cases of V786M to compare clinical outcomes across different treatment regimens.

Datasets

As a case report, the primary "dataset" is the patient’s clinical history and Next-Generation Sequencing (NGS) results. For broader context, the authors utilized:

  • The Cancer Genome Atlas (TCGA): Used to determine the prevalence of the V786M mutation (0.5% of 7,099 patients).
  • Protein Data Bank (PDB): Structures (e.g., PDB: 4LL0, 3VJO) were used as templates for the structural modeling and alignment.

Key Insights and Ideas

  • The "Dimerization Facilitator" Mechanism: Structural analysis showed that V786 is located at the N-terminus of the receptor’s dimerization interface. When Valine (V) mutates to Methionine (M), the larger side chain of Methionine protrudes into the interface. This stabilizes the "head-to-tail" active dimer configuration, essentially "locking" the receptor into an "on" position that drives oncogenesis.
  • Druggability Preserved: Crucially, the V786M mutation does not significantly alter the ATP-binding pocket (the Tyrosine Kinase Domain). This explains why the protein remains sensitive to TKIs, unlike other Exon 20 mutations that physically block drug entry.
  • Third-Gen Superiority: While literature suggests some V786M patients respond to 1st-gen TKIs (like gefitinib), this specific patient only responded to the 3rd-gen TKI (almonertinib). This suggests that 3rd-gen TKIs might have a higher affinity or better intracranial penetration, which was vital as this patient had brain metastases.

Key Results

  • Clinical Response: After failing chemotherapy + ICI (PFS 12m) and a 1st-gen TKI (which resulted in disease progression in just 1 month), the patient started almonertinib.
  • Quantitative Outcome: Within one week of almonertinib, clinical symptoms (fatigue, dizziness) improved. Follow-up imaging confirmed a Partial Response (PR), with significant shrinkage of both the primary lung tumor and intracranial metastases.
  • Durability: At the time of publication, the patient had achieved a Progression-Free Survival (PFS) of over 4 months on the 4th-line treatment, a significant result for a late-stage patient.

Limitations and Future Work

The primary limitation is the sample size (N=1). While the structural modeling provides a robust theoretical framework, clinical responses can vary based on a patient's unique subclonal landscape.

The authors also note the complexity of sequential therapy. The patient received an ICI (tislelizumab) before the TKI. In some cases, this sequence can increase the risk of severe side effects like interstitial pneumonitis, though this patient tolerated it well. Future research is needed to determine if 3rd-gen TKIs should be moved to the first-line setting for rare Exon 20 point mutations to avoid the "trial and error" seen in this case.

Summary updated

Abstract

Our data confirmed the activating role on EGFR V786M mutation. Together with structural predictions and clinical evidence for activity of TKIs against EGFR V786M mutations, these findings warrant further investigation.
BibTeX
@inproceedings{zhu2022lung,
  author = {Qi Zhu and Mingyun Jiang and Wenfei Li and Shuangli Sun and Jisheng Li and Justin Stebbing and Xiaodong Liang and Ling Peng},
  title = {{A Lung Cancer Patient Harboring a Rare Oncogenic EGFR Exon 20 V786M Mutation Responded to a Third-Generation Tyrosine Kinase Inhibitor: Case Report and Review of the Literature}},
  booktitle = {Frontiers in Oncology},
  year = {2022},
  doi = {10.3389/fonc.2022.912426},
}
Figure